Post Authorization Safety Study Moderna COVID-19 Primary Vaccine
NCT ID: NCT06006858
Last Updated: 2023-11-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1284 participants
OBSERVATIONAL
2022-11-03
2023-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Post Authorization Safety Profile of Booster IndoVac COVID-19 Vaccination
NCT06690502
Homologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine
NCT05933278
The Immunogenicity, Safety, and Effectiveness of the COVID-19 Inactivated Vaccine
NCT05126550
COVID-19 Booster Study in Healthy Adults in Australia
NCT05658523
A Study of the Effectiveness of Moderna COVID-19 Vaccine
NCT05933304
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Moderna COVID-19 Vaccine
Clinically healthy adults aged ≥ 18 years who received Primary Moderna COVID-19 Vaccine
Moderna COVID-19 Vaccine
Moderna COVID-19 Vaccine is provided as a white to off-white suspension for intramuscular injection. Each 0.5 mL dose of Moderna COVID-19 Vaccine contains 100 mcg of nucleoside-modified messenger RNA (mRNA) encoding the pre-fusion stabilized Spike glycoprotein (S) of SARS-CoV-2 virus.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Moderna COVID-19 Vaccine
Moderna COVID-19 Vaccine is provided as a white to off-white suspension for intramuscular injection. Each 0.5 mL dose of Moderna COVID-19 Vaccine contains 100 mcg of nucleoside-modified messenger RNA (mRNA) encoding the pre-fusion stabilized Spike glycoprotein (S) of SARS-CoV-2 virus.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects have been informed properly regarding the study and accepted to be enrolled in this study.
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Advisory Immunization Committee Indonesia
UNKNOWN
PT Bio Farma
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Julitasari Sundoro, MD
Role: PRINCIPAL_INVESTIGATOR
National Advisory Immunization Committee
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gambir Public Health Center
Jakarta Pusat, Jakarta Special Capital Region, Indonesia
Johar Baru Public Health Center
Jakarta Pusat, Jakarta Special Capital Region, Indonesia
Cempaka Putih Public Health Center
Jakarta Pusat, Jakarta Special Capital Region, Indonesia
Kemayoran Public Health Center
Jakarta Pusat, Jakarta Special Capital Region, Indonesia
Palmerah Public Health Center
Jakarta, , Indonesia
Kebon Jeruk Public Health Center
Jakarta, , Indonesia
Cengkareng Public Health Center
Jakarta, , Indonesia
Kebayoran Lama Public Health Center
Jakarta, , Indonesia
Tebet Public Health Center
Jakarta, , Indonesia
Setiabudi Public Health Center
Jakarta, , Indonesia
Pulo Gadung Public Health Center
Jakarta, , Indonesia
Duren Sawit Public Health Center
Jakarta, , Indonesia
Regional Hospital Duren Sawit
Jakarta, , Indonesia
Kramat Jati Public Health Center
Jakarta, , Indonesia
Cilincing Public Health Center
Jakarta, , Indonesia
Koja Public Health Center
Jakarta, , Indonesia
Tanjung Priok Public Health Center
Jakarta, , Indonesia
Pademangan Public Health Center
Jakarta, , Indonesia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COV19M-0422
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.